Google+ Badge

Thursday, May 7, 2015

Antibiotic Resistance Research:Redirects human antibodies to fight pathogenic bacteria ♦ Treatment reduces risk of recurrence of C. difficile ♦ Reverse bacterial resistance to antibiotics in lab

Molecular homing beacon redirects human antibodies to fight pathogenic bacteria With the threat of multidrug-resistant bacterial pathogens growing, new ideas to treat infections are sorely needed. Researchers report preliminary success testing an entirely novel approach -- tagging bacteria with a molecular "homing beacon" that attracts pre-existing antibodies to attack the pathogens
Researchers reverse bacterial resistance to antibiotics in lab The rise of antibiotic-resistant bacteria is a growing problem in the United States and the world. New findings by researchers in evolutionary biology and mathematics could help doctors better address the problem in a clinical setting.
Treatment reduces risk of recurrence of C. difficile infection Among patients with Clostridium difficile infection (CDI) who recovered following standard treatment with the antibiotics metronidazole or vancomycin, oral administration of spores of a strain of C. difficile that does not produce toxins colonized the gastrointestinal tract and significantly reduced CDI recurrence, according to a new study.
Fecal microbiota transplant cures C. diff, blocks multidrug resistant pathogens, A fecal microbiota transplant (FMT) not only cured a case of Clostridium difficile (C. diff) infection in a 66 year old man; it eliminated populations of multidrug resistant organisms both in the patient's gastrointestinal tract, and several other body sites, researchers report.
Bacteria research opens way for new antibiotics A target for the development of completely new antibiotics against disease-causing bacteria has been discovered by scientists. The discovery will also be useful in the biotechnology field for the development of a variety of marketable products and processes which rely on coupling biological molecules to cell surfaces.

No comments:

Post a Comment